Fushine(300497)2025-01-24 11:36Financial Performance Expectations - The company expects a net profit loss of between 22 million and 28 million yuan for 2024, compared to a loss of 20.08 million yuan in the same period last year[4]. - The projected operating revenue for 2024 is between 105 million and 130 million yuan, down from 160.97 million yuan in the previous year[4]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 26 million to 32 million yuan, compared to a loss of 19.76 million yuan last year[4]. Revenue Decline Factors - The decline in revenue is attributed to a challenging pharmaceutical market environment and increased competition, leading to lower product prices and higher raw material costs[8]. Investment and Growth Strategies - The company has increased its investment in synthetic biology and microbial protein sectors to create new growth points for 2025[8]. - The company plans to enhance management efficiency and actively respond to various risks and challenges for sustainable development[8]. Impairment and Non-Recurring Impacts - The impact of impairment provisions on profits is estimated to be between 10 million and 13 million yuan due to inventory and long-term asset impairment tests[8]. - Non-recurring gains and losses are expected to impact net profit by approximately 3 million to 4 million yuan[8]. Cash Flow and Reporting - Despite the challenges, the company's operating cash flow has shown growth during the reporting period[8]. - The detailed financial data for the 2024 annual performance will be disclosed in the annual report[9].